In AF patients, the current guidelines highlight the potential role of upstream therapies such as angiotensin-converting enzyme inhibitors, beta-blockers, and statins to prevent atrial remodeling as a rhythm control strategy (Hindricks et al., 2020). Here, ACE is linked to atrial fibrillation.